Disruption at a key California facility could tighten fuel markets, boosting margins for competing refiners in an already vulnerable region.
The approval covers a first-line maintenance treatment for an aggressive form of small cell lung cancer, a historically difficult-to-treat disease.
The ongoing government shutdown has postponed the release of key economic data, leaving the Federal Reserve and investors in the dark.
The regulator's green light for Rhapsido, a first-in-class oral treatment for chronic hives, positions the company to challenge injectable rivals.
Gene therapy candidate TSHA-102 for Rett syndrome receives key designation, paving the way for an accelerated regulatory pathway.
A multibillion-dollar AI agreement is in limbo as the US Commerce Department scrutinizes the UAE's ties to Beijing, potentially impacting Nvidia's growth.
The company outlined key milestones for its sublingual drug delivery platform, including a planned 2025 FDA submission for its high-dose aspirin.
Zepzelca combo becomes first approved maintenance treatment for extensive-stage small cell lung cancer, a historically difficult-to-treat disease.